Nurix Therapeutics (NRIX) Other Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has 3 years of Other Non-Current Liabilities data on file, last reported at $796000.0 in Q3 2021.

• Other Non-Current Liabilities for Q3 2021 came in at $796000.0, down 8.29% year-over-year; the trailing twelve-month figure through Aug 2021 was $796000.0 (down 8.29% YoY), and the FY2020 annual result was $850000.0, down 51.07% from the prior year.
• Other Non-Current Liabilities eased to $796000.0 in Q3 2021 per NRIX's latest filing, from $837000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $1.7 million in Q4 2019 and troughed at $796000.0 in Q3 2021.
• A 3-year average of $986666.7 and a median of $843500.0 in 2020 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2020 and 2021: Other Non-Current Liabilities sank 51.07% in 2020, then decreased 8.29% in 2021.
• A 3-year view of Other Non-Current Liabilities shows it stood at $1.7 million in 2019, then tumbled by 51.07% to $850000.0 in 2020, then retreated by 6.35% to $796000.0 in 2021.
• Business Quant data shows NRIX's Other Non-Current Liabilities at $796000.0 in Q3 2021, $837000.0 in Q2 2021, and $832000.0 in Q1 2021.